Enveda Biosciences

Enveda Biosciences is a biotechnology company that applies large-scale metabolomics, mass spectrometry, knowledge graphs and machine learning to characterize the molecules produced by living organisms, particularly medicinal plants, and to translate them into small-molecule drug candidates. The company frames the natural world as largely uncharacterized chemical space, arguing that purifying individual molecules from complex mixtures, resolving their structures and characterizing their activity has historically been too slow and costly for the pharmaceutical industry, and that its platform can read this chemistry at greater speed and scale.

The platform combines high-throughput experimentation and robotics with computational models, including a model that predicts chemical structures directly from mass spectrometry measurements, to build a biologically annotated dataset of small molecules that can be queried by chemical structure, biological activity and organ distribution. Outputs feed an internal therapeutic pipeline: as of mid-2024 the company had nominated a sixth New Chemical Entity development candidate and was advancing three lead programs toward parallel Phase I development, including an oral anti-inflammatory for atopic dermatitis and a program for inflammatory bowel disease targeting multiple cytokine signaling cascades in the gut. Other stated disease interests include fibrosis and neurodegeneration.

Founding story

Founder Viswa Colluru conceived Enveda while working as a product manager at Recursion Pharmaceuticals, where he drew lessons about challenging dogma, reasoning from first principles, and the gap between laboratory and clinical results. Rather than building digital representations of biology as Recursion does, he sought to build digital representations of chemistry to improve molecule selection. His upbringing in India, where his father ran a pharmacy selling plant-based Ayurvedic medicines alongside prescription drugs, informed the focus on natural products. The company was founded in 2019 without an academic lab or venture fund origin.

Business model

Enveda develops its own therapeutic assets, discovering and progressing novel small molecules through preclinical and clinical development rather than selling the platform as a standalone product.

Traction

By July 2023 the company reported having raised $175 million since its 2019 founding, after starting with roughly $225,000 and no proprietary IP or core technology. A June 2024 financing brought total capital raised to $230 million. The company reported a sixth development candidate nomination in 2024 and planned first clinical trial entries for its lead programs in late 2024 and early 2025.

Latest developments

In April 2026 Enveda appointed Christopher K. Porter, MBA, JD as Senior Vice President, Clinical Operations. The company continued to hire across supply chain, engineering, bioanalysis, in vivo pharmacology and ADME/formulation roles in Hyderabad, and was expected to enter its first assets into clinical trials.